

No.	Author	VTE vs. No-VTE	Incidence (n/N, %)	Age, year (Mean ± SD)	Male sex (n %)	BMI, kg/m ² (Mean ± SD)	Hypertension	Diabetes	Baseline CAD	Current or former Smoker	Malignancy
1	Artifon 2020	VTE	16/71 (22.5%)	60.2 ± 31	11 (68.7%)	27.2 ± 2.9	3 (19%)	0 (0%)	-	0 (0%)	0 (0%)
		No-VTE	55/71 (77.5%)	62.1 ± 20.9	32 (58.2%)	28 ± 6.2	26 (47%)	14 (25%)	-	6 (12%)	4 (7%)
2	Zhang 2020	VTE	66/143 (46.2%)	67 ± 12	36 (54.5%)	23.6 ± 2.9	28 (42.4%)	13 (19.7%)	9 (13.6%)	5 (7.6%)	3 (4.5%)
		No-VTE	77/143 (53.8%)	59 ± 16	38 (49.4%)	23.6 ± 3.1	28 (36.4%)	13 (16.9%)	8 (10.4%)	4 (5.2%)	4 (5.2%)
3	Rodrígueza 2020	VTE	23/156 (14.7%)	66.7 ± 15.2	14 (60.9%)	27.7 ± 5.5	-	-	-	-	2 (8.7%)
		No-VTE	133/156 (85.3%)	68.4 ± 14.4	88 (66.2%)	26.8 ± 3.9	-	-	-	-	14 (10.5%)
4	Cui 2020	VTE	20/81 (25%)	68.4 ± 9.1	-	-	-	-	-	-	-
		No-VTE	61/81 (75%)	57.1 ± 14.3	-	-	-	-	-	-	-
5	Trimaille 2020	VTE	49/289 (17%)	61.4 ± 15.0	33 (67.3%)	21 (45.7%)	25 (51.0%)	11 (22.4%)	3 (6.1%)	3 (6.1%)	2 (4.1%)
		No-VTE	240/289 (83%)	62.4 ± 17.4	138 (57.5%)	80 (37.2%)	107 (44.6%)	48 (20.0%)	15 (6.3%)	8 (3.3%)	6 (2.5%)
6	Maatman 2020	VTE	31/109 (28.45)	60 ± 17	20 (65%)	34.7 ± 12.7	17 (55%)	10 (32%)	1 (3.2%)	5 (16%)	-
		No-VTE	78/109 (71.6%)	62 ± 15	42 (54%)	34.8 ± 11.5	57 (73%)	33 (42%)	-	28 (36%)	-
7	Trigonis 2020	VTE	19/45 (42.2%)	64.1 ± 14	-	31.8 ± 5.8	-	-	-	-	-
		No-VTE	26/45 (52.8%)	58.3 ± 15.4	-	35.2 ± 11.3	-	-	-	-	-
8	Desborough 2020	VTE	10/66 (16.7%)	54 ± 15.5	8 (80%)	28.1 ± 8.4	5 (50%)	2 (20%)	1 (10%)	-	2 (20%)
		No-VTE	56/66 (83.3%)	59.4 ± 11.4	40 (71%)	29.9 ± 6	25 (45%)	25 (45%)	6 (11%)	-	3 (5%)
9	Koleilat 2020	VTE	18/135 (13.4%)	57.2 ± 12.1	11 (61.1%)	32 ± 6.1	13 (72.2%)	6 (33%)	1 (5.6%)	3 (16.7%)	3 (16.7%)
		No-VTE	117/135 (86.6%)	63.3 ± 15	61 (52.1%)	28.7 ± 6.1	81 (69.2%)	45 (38.5%)	15 (12.8%)	39 (33.6%)	17 (14.5%)
10	Hippensteel 2020	VTE	24/91 (27.4%)	55 ± 13	14 (58%)	32.1 ± 8.5	-	7 (32%)	14 (3%)	20 (4%)	0 (0%)
		No-VTE	67/91 (72.6%)	57 ± 17	39 (58%)	32.5 ± 10.4	-	21 (33%)	27 (17%)	22 (12%)	5 (3%)
11	Fauvel 2020	VTE	103/1240 (8.3%)	63 ± 16	73 (70.9%)	27.3 ± 5.6	44 (42.7%)	19 (18.4%)	9 (8.7%)	44 (42.7%)	8 (7.8%)

		No-VTE	1137/1240 (91.7%)	64 ± 17	648 (57.0%)	28.2 ± 6.3	515 (45.7%)	249 (22.0%)	124 (10.9%)	515 (45.7%)	159 (14.0%)
12	Soumagne 2020	VTE	55/375	61.1 ± 9.1	46 (84%)	29.6 ± 4.7	26 (53%)	12 (22%)	8 (15%)	-	4 (7%)
		No-VTE	320/375	63.9 ± 10.3	242 (76%)	29.8 ± 5.6	190 (59%)	87 (27%)	28 (9%)	-	40 (13%)

1

2

Continued

No.	Author	VTE history (n, %)	D-Dimer $\mu\text{g/mL}$ (mean \pm SD)	Fibrinogen (g/L) (mean \pm SD)	PT (mean \pm SD)	APTT (mean \pm SD)	Prophylactic anticoagulation (n, %)	Therapeutic anticoagulation (n, %)	Corticosteroid (n, %)	Antibiotics (n, %)	ICU n (%)	Mortality (n, %)	Comments
1	Artifon 2020	2 (13%)	2.6 \pm 3.3	5.5 \pm 1.6	-	-	16 (100%)	-	3 (20%)	16 (100%)	8 (50%)	-	
		3 (5%)	0.8 \pm 0.5	5.3 \pm 1.8	-	-	54 (99%)	-	12 (22%)	49 (89%)	5 (9.1)	-	
2	Zhang 2020	0 (0.0%)	5.6 \pm 4.2	-	14.3 \pm 1.6	36.4 \pm 8.1	22 (33.3%)	59 (89.4%)	34 (51.5%)	56 (84.8%)	12 (18.2%)	23 (34.8%)	
		1 (1.3%)	1.6 \pm 2.3	-	13.1 \pm 1.3	34.2 \pm 5.9	31 (40.3%)	0 (0.0%)	29 (37.8%)	61 (79.2%)	3 (3.9%)	9 (11.7%)	
3	Rodrígueza 2020	-	5.3 \pm 5.7	-	-	-	-	-	-	-	3 (13.0%)	-	37 patients were excluded due to receiving therapeutic doses of anticoagulation.
		-	2.4 \pm 1.6	-	-	-	-	-	-	-	13 (9.8%)	-	
4	Cui 2020		5.2 \pm 3.0	-	15.4 \pm 1.0	39.9 \pm 6.4	-	-	-	-	-	8/20	All ICU patients. 37 (46%) patients were males. 20 (25%) patients had hypertension. 8 (10%) patients had diabetes. 10 (12%) patients had baseline CAD. 35 (43%) patients were current or former smokers.

			0.8 ± 1.2	-	15.6 ± 1.0	35.6 ± 4.5	-	-	-	-	-	0/61	
5	Trimaille 2020	5 (10.2%)	5.2 ± 5.5	6.4 ± 1.8	84 ± 18	1.2 ± 0.3	1 (2%)	-	-	-	21 (43.8%)	6 (12.2%)	
		23 (9.6%)	1.8 ± 2.5	6.4 ± 1.6	85 ± 20	1.2 ± 0.4	31 (12.9%)	-	-	-	51 (21.3%)	18 (7.5%)	
6	Maatman 2020	2 (6.7%)	1.7 ± 2.4	6.3 ± 2.4	-	-	1 (2.0%)	30 (27.5%)	-	-	31 (100%)	(8) 26%	All patients were included from the ICU.
		0 (0%)	0.5 ± 0.4	6.9 ± 2.7	-	-	31 (12.9%)	78/109 (71.6%)	-	-	78 (100%)	19 (24%)	
7	Trigonis 2020	-	8.4 ± 7.8	-	-	-	1 (5.3%)	6 (32%)	-	-	-	-	All patients were on some form of chemical prophylaxis from the date of their admission. All patients were admitted to the ICU.
		-	3.4 ± 2.7	-	-	-	3 (11.5%)	10 (38%)	-	-	-	-	
8	Desborough 2020	1 (10%)	161.6 ± 336.1	7.9 ± 2.8		1.2 ± 0.3	-	-	-	-	-	-	All patients were given thromboprophylaxis, admitted to critical care. 11 patients (17%) were treated with treatment dose anticoagulation.
		4 (7%)	1.7 ± 2.1	6.1 ± 2		1.2 ± 0.3	-	-	-	-	-	-	
9	Koleilat 2020	1 (5.6%)	12.5 ± 12.8	5.3 ± 1.5		36.8 ± 8.3	12 (85.7%)	18 (100%)	9 (50%)	-	-	2 (11.1%)	All patients admitted to the ICU.

		9 (7.9%)	5.3 ± 5.3	6.6 ± 1.8		54.4 ± 8	74 (63.2%)	21 (17.9)	36 (30.8%)	-	-	18 (16.4%)	
10	Hippensteel 2020	-	0.5 ± 0.3	0.5 ± 0.3	-	-	-	13 (54.3%)	-	-	19 (79%)	2 (9%)	Twenty-four patients (261%) were found to have VTE during their hospitalization.
		-	1.8 ± 6	1.8 ± 6	-	-	-	-	-	-	42 (63%)	20 (30%)	
11	Fauvel 2020	10 (9.7%)	3.5 ± 4.4	6.3 ± 2.0	83 ± 16	1.1 ± 0.2	18 (18.4%)	5 (5.1%)	10 (9.7%)	86 (83.5%)	32 (31.1%)	9 (8.7%)	All medication received before PE.
		88 (7.7%)	1.4 ± 4.1	6.1 ± 1.6	85 ± 18	1.2 ± 0.3	720 (67.0%)	94 (8.8%)	63 (5.5%)	853 (75.0%)	153 (13.5%)	142 (12.5%)	
12	Soumagne 2020	11 (20%)	-	-	-	-	-	-	13 (26%)	-	-	25 (45%)	All medications received before PE.
		24 (8%)	-	-	-	-	-	-	64 (21%)	-	-	201 (63%)	

Table 1. Characteristics of included studies.